Gynecologic Cancer | Norton Healthcare

Indication: Gynecologic Cancer

A Randomized Phase III Evaluation of Docetaxel and Gemcitaine Plus G-CSF with Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF with Placebo in the Treatment of Recurrent of Advanced Leiomyosarcoma of the Uterus

Sub-indication: Gynecologic Cancer

Drug Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: Gynecologic Oncology Group (GOG)

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.